330 related articles for article (PubMed ID: 28057891)
1. Prostate cancer, PI3K, PTEN and prognosis.
Wise HM; Hermida MA; Leslie NR
Clin Sci (Lond); 2017 Feb; 131(3):197-210. PubMed ID: 28057891
[TBL] [Abstract][Full Text] [Related]
2. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
[TBL] [Abstract][Full Text] [Related]
3. The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer.
Turnham DJ; Bullock N; Dass MS; Staffurth JN; Pearson HB
Cells; 2020 Oct; 9(11):. PubMed ID: 33105713
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of PTEN loss in prostate cancer.
Jamaspishvili T; Berman DM; Ross AE; Scher HI; De Marzo AM; Squire JA; Lotan TL
Nat Rev Urol; 2018 Apr; 15(4):222-234. PubMed ID: 29460925
[TBL] [Abstract][Full Text] [Related]
5. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
6. PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate.
Wise HM; Harris A; Kriplani N; Schofield A; Caldwell H; Arends MJ; Overton IM; Leslie NR
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291720
[TBL] [Abstract][Full Text] [Related]
7. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
Cully M; You H; Levine AJ; Mak TW
Nat Rev Cancer; 2006 Mar; 6(3):184-92. PubMed ID: 16453012
[TBL] [Abstract][Full Text] [Related]
8. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
9. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Saal LH; Johansson P; Holm K; Gruvberger-Saal SK; She QB; Maurer M; Koujak S; Ferrando AA; Malmström P; Memeo L; Isola J; Bendahl PO; Rosen N; Hibshoosh H; Ringnér M; Borg A; Parsons R
Proc Natl Acad Sci U S A; 2007 May; 104(18):7564-9. PubMed ID: 17452630
[TBL] [Abstract][Full Text] [Related]
10. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.
Wu RC; Young IC; Chen YF; Chuang ST; Toubaji A; Wu MY
Nat Commun; 2019 Sep; 10(1):4332. PubMed ID: 31551414
[TBL] [Abstract][Full Text] [Related]
11. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
Haddadi N; Lin Y; Travis G; Simpson AM; Nassif NT; McGowan EM
Mol Cancer; 2018 Feb; 17(1):37. PubMed ID: 29455665
[TBL] [Abstract][Full Text] [Related]
12. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
13. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
14. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
15. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
[TBL] [Abstract][Full Text] [Related]
16. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
17. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
18. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
Luo J; Sobkiw CL; Logsdon NM; Watt JM; Signoretti S; O'Connell F; Shin E; Shim Y; Pao L; Neel BG; Depinho RA; Loda M; Cantley LC
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10238-43. PubMed ID: 16006513
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.
Xi Y; Chen Y
J Cell Biochem; 2015 Sep; 116(9):1837-47. PubMed ID: 25773992
[TBL] [Abstract][Full Text] [Related]
20. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
